Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (1) · (multiple, generic dominant) (1) · Toradol (IV/IM, US brand discontinued), Sprix (nasal spray), Acular and Acuvail (ophthalmic) (1)

Analgesic (2) · Opioid (2) · Prodrug (1) · [[:Category:Analgesics|Analgesic (opioid-sparing parenteral)]] (1) · [[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID)]] (1)

None (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (1) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1)

None (1) · Adult: 15–60 mg every 4 hours as needed. (1) · IM: 60 mg single dose or 30 mg every 6 hours. IV: 30 mg every 6 hours. Oral (continuation only): 10-20 mg every 4-6 hours. Sprix nasal: 31.5 mg every 6-8 hours. '''Maximum 5 days total combined use''' (1)

None (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) · Tablets 10 mg; injection 15 mg/mL and 30 mg/mL; nasal spray 15.75 mg/spray (Sprix); ophthalmic solution 0.4%, 0.45%, 0.5% (1)

None (1) · 120 mg/day (IV/IM); 40 mg/day (oral); '''5-day maximum total combined therapy''' to mitigate the GI bleeding, AKI, and platelet dysfunction risks (1) · 360 mg/day (1)

None (1) · IM (1) · intranasal (1) · IV (1) · ophthalmic (1) · Oral (continuation only) (1) · PO (only formulation marketed in the US). (1)

None (1) · 30 minutes (IM); 30-60 minutes (oral) (1) · 30–60 min (PO) (1)

None (1) · 4-6 hours (1) · 4–6 hours (1)

None (1) · 2.5–3 hours (1) · 5-6 hours'"`UNIQ--ref-00000020-QINU`"' (1)

None (1) · ~100% (oral, but oral use is limited to continuation from parenteral)'"`UNIQ--ref-00000021-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (1) · Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning; contraindicated from 30 weeks. Specifically contraindicated in labor and delivery due to inhibition of uterine contractions'"`UNIQ--ref-00000022-QINU`"' (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)

None (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)